Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology – Seeking Alpha
Seeking Alpha |
Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology
Seeking Alpha Bluebird Bio expands license agreement for two additional TCR targets. There is a need for TCRs, because CAR–T are strong but can't target tumor proteins that are inside of cells only those that are expressed on the cell's surface. Bluebird Bio will … bluebird bio expands US$1bn deal with MediGene |
